|
Press Releases
-
February 12, 2010
BioSyntech Announces Third Quarter Fiscal 2010 Financial Results
LAVAL, Quebec - February 12, 2010 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for the third quarter of fiscal 2010, ended December 31, 2009.
More
-
January 07, 2010
BioSyntech Issues Common Shares as Payment of Interest
LAVAL, Quebec, January 7, 2010 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing novel products in regenerative medicine, today announced that it has exercised its option to issue 8,265,921 common shares to its holders of 2008 Debentures in payment of the $739,800.00 interest payable on December 31,
More

Archives
-
December 02, 2009
BioSyntech Announces Management Changes
LAVAL, Quebec – December 2, 2009 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that Ms. Antoinette Lizzi, Chief Financial Officer, will leave the Company effective December 2, 2009 and Ms. Catherine Auld, CA, will join the Company as Chief Financial Officer.
More
-
November 16, 2009
BioSyntech Announces Second Quarter Fiscal 2010 Financial Results
LAVAL, Quebec - November 16, 2009 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for the second quarter of fiscal 2010, ended September 30, 2009.
More
-
October 16, 2009
BioSyntech Announces Closing of $3.1 Million Rights Offering
LAVAL, Quebec – October 16, 2009 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, announces the successful closing of its previously announced offering of rights to purchase 310,000 units,
More
-
September 09, 2009
BioSyntech Presents Bst-Cargel® Cartilage Repair Trial Design at the 2009 World Congress on Osteoarthritis in Montreal
LAVAL, Quebec – September 9, 2009 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced it will present a poster entitled “Challenges in Designing Randomized Clinical Trials for Cartilage Repair: The BST-CarGel® Experience”
More
-
August 31, 2009
BioSyntech Announces Filing of Final Prospectus for $3.1 Million Rights Offering
LAVAL, Quebec - August 31, 2009 - BioSyntech, Inc. (“BioSyntech”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has filed a final short form prospectus in respect of the distribution to its existing shareholders of rights exercisable to purchase 310,000 units, each comprised of $10 principal amount of subordinated secured convertible debentures and 91 common share purchase warrants, at a price of $10 per unit, representing gross aggregate proceeds of up to $3,100,000 to BioSyntech.
More
-
August 24, 2009
BioSyntech Appoints Chairman and Additional Director to Its Board
LAVAL, Quebec - August 24, 2009 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced it has appointed two additional members to its Board of Directors, Mr. André Archimbaud and Ms. Jeanne Bertonis, Chief Executive Officer for BioSyntech. Mr. Archimbaud will serve as Chairman of the Board.
More
-
August 24, 2009
BioSyntech Announces Completion of $1.4 Million Private Placement and Launch of $3.1 Million Rights Offering
LAVAL, Quebec - August 24, 2009 - BioSyntech, Inc. (“BioSyntech”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has completed its previously announced private placement of an aggregate of 140,000 units of BioSyntech, each comprised of $10 principal amount of subordinated secured convertible debentures and 91 common share purchase warrants, to Highland Crusader Offshore Partners, L.P. (“Highland”), ProQuest Investments III, L.P. (“ProQuest”), Fonds de Solidarité des travailleurs du Québec (F.T.Q.) (“FSTQ”), A. M. Papp
More
-
August 14, 2009
BioSyntech Appoints Chief Executive Officer
LAVAL, Quebec - August 14, 2009 - BioSyntech, Inc. (TSX: BSY) a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has appointed Ms. Jeanne Bertonis, MBA, M.Sc., to the role of Chief Executive Officer. The Company previously announced that Ms. Bertonis was retained by BioSyntech as a consultant to assist the Company with its research and development, regulatory, strategic planning and business development strategies.
More
-
August 14, 2009
BioSyntech Announces First Quarter Fiscal 2010 Financial Results
LAVAL, Quebec - August 14, 2009 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for the first quarter of fiscal 2010, ended June 30, 2009.
More
-
August 14, 2009
BioSyntech Announces $4.5 Million Financing
LAVAL, Québec — August 14, 2009 — BioSyntech, Inc. (“BioSyntech”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has entered into an agreement with ProQuest Investments III, L.P. (“ProQuest”), Fonds de Solidarité des travailleurs du Québec (F.T.Q.) (“FSTQ”), Highland Crusader Offshore Partners, L.P. (“Highland”) and A. M. Pappas Life Science Ventures III, LP and PV III CEO Fund, LP (collectively, “Pappas” and, together with ProQuest, FSTQ and Highland, the “Investors”) pursuant to which:
More
-
July 24, 2009
BioSyntech Appoints Chief Financial Officer
LAVAL, Quebec — July 24, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has appointed Ms. Antoinette Lizzi, CMA, to the position of Chief Financial Officer.
More
-
July 21, 2009
BioSyntech Appoints PricewaterhouseCoopers as Financial Advisor
LAVAL, Quebec — July 21, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has retained the services of PricewaterhouseCoopers LLP to act as its financial advisor with respect to the Company’s formal review of strategic alternatives including, but not limited to, a commercial partnership involving its cartilage repair device BST-CarGel® or a corporate sale of the Company. There can be no assurance that this strategic review will result in any specific transactions and no timetable has been set fo
More
-
July 15, 2009
BioSyntech Announces Management Changes
LAVAL, Quebec — July 15, 2009 — BioSyntech, Inc. (TSX: BSY) announced today that it has retained the services of Ms. Jeanne Bertonis to assist the Company with its research and development, regulatory, strategic planning and business development strategies. Ms. Bertonis has 25 years of experience in the drug, device and biomaterials industries. She held the positions of Chief Business Officer and Vice President, Corporate Development for Angiotech Pharmaceuticals from 2000-2006,
More
-
July 06, 2009
BioSyntech Announces Appointment of New Board Member
LAVAL, Quebec — July 6, 2009 — BioSyntech, Inc. (TSX: BSY) (the Company) announced today the appointment of Mr. Lee E. Brown as member of the Board of Directors. Mr. Brown was designated by Highland Capital Management to replace Mr. Nick Losey on the Company’s Board. Under the terms of an underwriting agreement signed in connection with the July 2008 debenture financing, Highland Capital Management has the right to nominate one member to the Board of the Company.
More
-
June 29, 2009
BioSyntech Announces Year End and Fourth Quarter Fiscal 2009 Financial Results and Management Changes
LAVAL, Quebec — June 29, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for the fiscal year, ending March 31, 2009.
More
-
June 17, 2009
BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel® Cartilage Repair Device
LAVAL, Quebec — June 17, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced statistically significant results from an analysis of patients who completed their 12 month follow-up in the BST-CarGel® randomized clinical trial.
More
-
June 11, 2009
BioSyntech Gives Notice to Debentureholders and
Announces Resignation of Board Member
LAVAL, Quebec — June 11, 2009 — BioSyntech, Inc. (TSX: BSY) (the Company) gave notice to its debentureholders that it exercised its right to make the interest payment of $745,800 due on June 30, 2009 by issuing common shares. The number of common shares to be issued on June 30, 2009 will be equal to the amount of the interests, divided by 95% of the volume weighted average trading price per common share for the five trading days immediately preceding.
More
-
May 01, 2009
BioSyntech Announces Resignation of Board Member
and Appointment of New Board Member
LAVAL, Quebec — May 1, 2009 — BioSyntech, Inc. (TSX: BSY) (the Company) announced today that Mr. Winston Black has tendered his resignation as member of the Board. This resignation is subsequent to Mr. Black’s resignation from Highland Capital Management. Under the terms of an underwriting agreement signed in connection with the July 2008 debenture financing, Highland Capital Management has the right to nominate one member to the Board of the Company.
More
-
March 30, 2009
BioSyntech Forms Special Committee
LAVAL, Quebec — March 30th, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that its Board of Directors has formed a Special Committee to review the strategic alternatives of the Company, including partnering activities with the orthopaedic industry,
More
-
March 12, 2009
BioSyntech to Conduct Substantial Interim Analysis on Half of Enrolled Patients from BST-CarGel® Pivotal Trial
LAVAL, Quebec — March 12, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it will conduct an interim analysis of the available clinical data from 40 subjects who have completed their 12 month follow-up in the 80 subject trial for its cartilage repair device, BST-CarGel®. The Company expects to have the results from this analysis available in the second quarter of 2009.
More
-
February 20, 2009
BioSyntech Appoints Chief Financial Officer
LAVAL, Quebec — February 20, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has appointed Mr. Louis Lemire, CA, to the to the position of Chief Financial Officer. Mr. Lemire joined the Company as a consultant in October 2008 and was appointed Vice President, Finance in December 2008.
More
-
February 13, 2009
BioSyntech Announces Third Quarter Fiscal 2009 Financial Results
LAVAL, QC, Feb. 13 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for the third quarter of fiscal 2009, ended December 31, 2008.
More
-
February 02, 2009
BioSyntech achieves enrolment goal for pivotal trial of BST-CARGEL®, its cartilage repair device
LAVAL, Quebec — February 2, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has completed enrolment for the Canadian-European pivotal trial of its cartilage repair device, BST-CarGel®. The Company achieved its planned objective of enrolling 80 patients into the randomized trial.
More
-
January 26, 2009
BioSyntech Announces Changes to Board of Directors
LAVAL, QC, Jan. 26 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that Dr. Amine Selmani has resigned from its Board of Directors effective January 23, 2009. Dr. Selmani is the founder of BioSyntech and was its Chief Executive Officer from 1995 to 2004 and subsequently Chairman of the Board of Directors until 2006.
More
-
January 13, 2009
BioSyntech to Conclude Enrolment for
Pivotal BST-CarGel® Trial in February 2009
LAVAL, Quebec — January 12, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it will conclude enrolment next month for the Canadian-European pivotal trial of its cartilage repair device, BST-CarGel®. To date, the Company has enrolled more than 70 subjects and participating clinical sites will be permitted to enrol additional subjects until February 10th, 2009.
More

-
December 17, 2008
BioSyntech Announces Management Change
LAVAL, Quebec — December 16, 2008 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that Mr. Francois Michaud has tendered his resignation as CFO, effective February 16, 2009.
More
-
November 13, 2008
BioSyntech Announces Second Quarter 2009 Financial Results
LAVAL, Quebec — November 13, 2008 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for the second quarter of fiscal 2009, ended September 30, 2008.
More
-
October 17, 2008
BioSyntech Announces Resignation of CEO
and Appointment of New Board Member
LAVAL, Quebec — October 17, 2008 — BioSyntech, Inc. (TSX: BSY) (the Company) announced today that Mr. Claude LeDuc has tendered his resignation, effective December 31, 2008, as CEO of the Company to pursue other interests. He also resigned immediately as a member of the Board.
More
-
August 12, 2008
BioSyntech Announces First Quarter 2009
Financial Results
LAVAL, Quebec — August 12, 2008 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for first quarter of its fiscal year 2009, ended June 30, 2008.
More
-
July 22, 2008
BioSyntech Appoints New Board Members
Laval, Québec, July 22, 2008 — BioSyntech, Inc. (the “Company”) (TSX:BSY) is pleased to announce that Mr. Michel Lagueux, Dr. Karen Hong, Mr. Eric W. Linsley and Mr. Winston Black have been appointed to the Board of Directors, effective immediately.
More
-
July 18, 2008
BioSyntech Announces Exercise of Over-Allotment Option
Laval, Québec, July 18, 2008 — BioSyntech, Inc. (the “Company”) (TSX:BSY) is pleased to announce that as part of the exercise of the over-allotment option in its previously announced bought deal,
More
-
July 15, 2008
BioSyntech Completes $11 Million Bought Deal
Laval, Québec, July 15, 2008 — BioSyntech, Inc. (the “Corporation”) (TSX:BSY) is pleased to announce that it has closed its previously announced bought deal.
More
-
July 08, 2008
BioSyntech, Inc. Announces Filing of Final Prospectus and Obtention of Conditional Listing Approval from the TSX and Provides an Update on Its Convertible Debenture Offering
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
More
-
June 27, 2008
BioSyntech Announces 2008 Year-End
Financial Results and the Adoption of a New Strategic Plan
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
More
-
June 20, 2008
BioSyntech Announces Increase to Bought Deal
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
More
-
June 18, 2008
BioSyntech Responds To TSX Listing Review
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
More
-
June 16, 2008
BioSyntech Announces $10 Million Bought Deal Financing
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
More
-
April 24, 2008
BioSyntech Announces BST-DermOnTM Abstract Selected For Poster Presentation at the 2008 World Union of Wound Healing Societies Congress
LAVAL, Quebec, April 24, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing novel products in regenerative medicine, today announced that its abstract summarizing the safety and effectiveness of BST-DermOn™ in promoting the healing of various types of chronic wounds that have failed previous treatments,
More
-
April 07, 2008
BioSyntech Receives ISO13485:2003 Certification For Its Quality Management System
LAVAL, Quebec, April 07, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing novel products in regenerative medicine, today announced that it has achieved international certification under the stringent and globally recognized ISO 13485:2003
More
-
March 17, 2008
BioSyntech Announces Positive Preliminary Interim Data
for BST-CarGel® Clinical Trial
LAVAL, Quebec, March 17, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing novel products in regenerative medicine, today announced it has received positive preliminary results from a prospectively planned six-month interim analysis of its Canadian-European pivotal clinical trial for BST-CarGel®.
More
-
March 04, 2008
BioSyntech Announces Five Poster Presentations at 54th Annual Meeting of the Orthopaedic Research Society
LAVAL, Quebec — March 4, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that five abstracts have been selected for presentation as posters at the 54th Annual Meeting of the Orthopaedic Research Society (“ORS”) held from March 2-5, 2008 in San Francisco, California.
More
-
February 14, 2008
BioSyntech announces third quarter 2008 financial results
LAVAL, Quebec — February 13, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial results for the three and nine-month periods ended December 31, 2007.
More

-
November 27, 2007
BioSyntech Awarded 2007 Innovation Award from ADRIQ
LAVAL, Quebec — November 27, 2007 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced it has been awarded the 2007 Innovation Award in the “Partnership” category by the Association de la Recherche Industrielle du Quebec (ADRIQ) for its successful partnership with the École Polytechnique de Montréal (École Polytechnique).
More
-
November 12, 2007
Biosyntech Announces Second Quarter 2008 Financial Results
LAVAL, Quebec — November 12, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial results for the three and six-month periods ended September 30, 2007.
More
-
August 13, 2007
BioSyntech announces first quarter 2008
financial results
LAVAL, Quebec, Canada — August 13, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced financial results for the first quarter ended June 30, 2007.
More
-
July 11, 2007
Biosyntech appoints new vice president, regulatory affairs and quality
LAVAL, Quebec, Canada — July 11, 2007 —- BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX: BSY) today announced that Mrs. Flor del Pilar Arana has been appointed Vice President, Regulatory Affairs and Quality.
More
-
June 29, 2007
BioSyntech announces fourth quarter and 2007 year-end
financial results
LAVAL, Quebec, Canada — June 29, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY) today announced financial results for the fourth quarter and fiscal year ended March 31, 2007.
More
-
June 14, 2007
BioSyntech reaches significant BST-CarGel® clinical milestone
LAVAL, Quebec, Canada — June 14, 2007 — BioSyntech Inc. (TSX: BSY) announced today that it has completed the enrolment of a 20 patient subset of its ongoing Canadian-European BST-CarGel® pivotal trial. The data collected from these patients will be submitted to the U.S. Food and Drug Administration as a pilot study in support of an Investigational Device Exemption (IDE) for a US pivotal trial.
More
-
April 02, 2007
BioSyntech announces refinancing of loan
LAVAL, Québec, Canada —April 2, 2007 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX: BSY) today announced that it has entered into a formal agreement with the Business Development Bank of Canada (the “BDC”), to refinance part of their loan of $2,500,000 by way of conventional mortgage.
More
-
February 14, 2007
BioSyntech reports its third quarter results
LAVAL, Québec, Canada — February 14, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY) today reported its results for its third quarter and nine-month period ended December 31, 2006.
More
-
February 08, 2007
BioSyntech announces start of patient recruitment into
BST-DermOnTM pivotal clinical trial
LAVAL, Quebec, Canada — February 8, 2007 — BioSyntech Inc. (TSX: BSY) announced today the start of recruitment into its Canadian pivotal clinical trial for BST-DermOnTM, a medical device designed to repair chronic wounds and based on the natural polysaccharide chitosan. Dr. Gary Sibbald, an internationally recognized leader in the field of dermatology and wound repair, is the Principal Investigator for this trial.
More

-
December 04, 2006
Monday, December 4 - BioSyntech, Inc. Opens the Markets
Claude LeDuc, CEO of BioSyntech, Inc., opened the markets today. BioSyntech is a biotechnology company specializing in the discovery, development, and manufacturing of innovative, cost-effective, and physician-friendly therapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech trades on TSX under the stock symbol BSY.
More
-
November 29, 2006
BioSyntech reports second quarter results
LAVAL, Québec, Canada — November 29, 2006 — BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX: BSY) today reported its results for the second quarter and six-month period ended September 30, 2006.
More
-
November 20, 2006
BioSyntech signs scientific collaboration agreement with Nicholas Piramal
Laval, Quebec, Canada — November 20, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX:BSY) is pleased to announce the signing of a scientific collaboration between the Company and their biopharmaceutical partner Nicholas Piramal.
More
-
October 30, 2006
BioSyntech shares begins trading on the TSX today
LAVAL, Québec, Canada — October 30, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) is pleased to announce that its common shares will commence trading on the Toronto Stock Exchange ("TSX") at the open of trading today, Monday October 30, 2006 under the symbol “BSY”.
More
-
October 11, 2006
BioSyntech Receives Notice of Allowance from
the US Patent and Trademark Office
on Key BST-CarGel® Patent
LAVAL, Québec, Canada — October 11, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today that on September 20, 2006, it received a Notice of Allowance from the US Patent and Trademark Office on their key BST-CarGel® patent entitled, “Composition and method for the repair and regeneration of cartilage and other tissues”. BST CarGel®, the Company's lead product,
More
-
September 29, 2006
BioSyntech announces conditional approval for listing on the Toronto Stock Exchange
LAVAL, Québec, Canada — September 29, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) is pleased to announce that its application to graduate to the Toronto Stock Exchange has been approved, subject only to the filing of final documentation.
More
-
September 25, 2006
Annual meeting of stockholders of BioSyntech, Inc.
LAVAL, QUEBEC, September 25, 2006 – Mr. Joseph Benarrosh, Chairman of the Board announces the Annual Meeting of Stockholders of BioSyntech, Inc.
More
-
August 25, 2006
BioSyntech reports first quarter results
LAVAL, Québec, Canada — August 25, 2006 — BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX-V: BSY) today reported its results for the first quarter ended June 30, 2006.
More
-
August 24, 2006
BioSyntech receives approval for Canadian BST-DermOn®
pivotal clinical trial
LAVAL, Quebec, Canada — August 24, 2006 — BioSyntech Inc. (TSX-V: BSY) announced today that it has received approval from Health Canada, Therapeutic Products Directorate, Medical Devices Bureau, to begin enrolling subjects in its pivotal clinical trial for BST-DermOn®, a medical device designed to repair chronic wounds.
More
-
August 08, 2006
BioSyntech strengthens management team with key appointments.
Company names François Michaud as chief financial officer and Richard Lacombe as vice-president clinical affairs
LAVAL, Québec, Canada — August 8, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) is pleased to announce the appointments of Mr. François Michaud C.A., C.M.A., as Chief Financial Officer and Mr. Richard Lacombe Ph.D., M.B.A., as Vice-President Clinical Affairs of the Company.
More
-
July 28, 2006
BioSyntech reports major progress in fiscal 2006
Strengthens balance sheet with $28 million financing
Enhances board with additional members
LAVAL, Québec, Canada — July 28, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today reported its results for the fiscal year ended March 31, 2006.
More
-
June 13, 2006
BioSyntech strengthens board with new member
LAVAL, Québec, Canada — June 13, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today announced the appointment of Dr. Joyce Tsang to its Board of Directors. Dr. Tsang is the representative for ProQuest Investments, which invested in the Company’s recent financing.
More
-
May 25, 2006
BioSyntech appoints new board member
LAVAL, Québec, Canada — May 25, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today announced the appointment of Rudy Huber to its board of directors. Mr. Huber is the representative for an institution that invested in the Company’s recent financing.
More
-
May 10, 2006
BioSyntech grants stock options
LAVAL, Quebec, Canada – May 9, 2006 – In accordance with its continuous disclosure obligations, BioSyntech, Inc. (TSX-V: BSY) announces the grant of options to acquire 50,000 common shares of its capital stock at a price of $0.49 per share for a period of five years to a Board Director.
More
-
May 03, 2006
BioSyntech closes its private placement for a total of $21 Million with a $3 Million third and final tranche
LAVAL, Quebec, Canada – May 3rd, 2006 – BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today the closing of the third tranche of its previously-announced financing. This final tranche involved the issuance of 7,125,000 Units at $0.42 per Unit for a total of $2,996,700. This brings the total financing to $21 million for the issuance of 50,000,000 Units. Each Unit consisted of one common share and half a warrant. Each full warrant entitles the holder to purchase one share at $0.65 prior to March 31, 2009.
More
-
April 18, 2006
BioSyntech closes $8 Million second tranche of its private placement and increases total offering to $21,7 Million
LAVAL, Quebec, Canada – April 17, 2006 – BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today that it has increased the size of its previously announced private placement to $21,700,000, representing an aggregate of 51,666,666 units, at a price of $0.42 per unit, to accommodate the subscription of two strategic investors.
More
-
March 31, 2006
BIOSYNTECH, INC. ANNOUNCES FIRST CLOSING OF ITS PRIVATE PLACEMENT FOR AN AMOUNT OF $10 MILLION
LAVAL, Quebec, Canada – March 31, 2006 – BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today a first closing of its private placement involving the issuance of 23,810,000 units at a price of $0.42 per unit for gross proceeds of $10,000,200. Each unit consists of one common share of the Company and one half of one warrant. Each warrant entitles the holder to purchase, for a period of three years, one common share at a price of $0.65 per share.
More
-
March 20, 2006
BioSyntech Inc. announces new closing date for its private placement, continuation under the Canada Business Corporations Act and appointment of new chairman
LAVAL, Quebec, Canada – March 20, 2006 – BioSyntech Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today the appointment of Joseph Benarrosh as Chairman of its board of directors, following the resignation of Amine Selmani, who remains as a board member. Mr. Benarrosh has been a board member of the Company since 2004.
More
-
February 28, 2006
BioSyntech Inc. announces proposed private placement
LAVAL, Quebec, Canada – February 28, 2006 – BioSyntech Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today that it has retained the services of Desjardins Securities Inc. as lead agent and Dundee Securities Corporation (together, the “Agents”) for a private placement of 23,810,000 units of the Company at a price of $0.42 per unit, for gross proceeds of $10,000,200.
More
-
February 24, 2006
BioSyntech reports its third quarter results
LAVAL, Québec, Canada — February 24, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today reported its results for its third quarter and nine-month period ended December 31, 2005.
Highlights and subsequent events:
More
-
February 16, 2006
BioSyntech announces extension of BDC loan
LAVAL, Quebec, Canada — February 16, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX-V: BSY) today announced that it has negotiated the extension until February 15, 2009 of the $2,500,000 loan obtained in 2002 from the Business Development Bank of Canada (the “BDC”), on the same terms and conditions. All outstanding interest due on the initial loan, which had been capitalized since disbursement, was paid.
More
-
February 09, 2006
BioSyntech closes transaction with Kuhnil Pharma Co. LTD
LAVAL, Quebec, Canada — February 9, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) today announced the closing of the transaction with Kuhnil Pharma Co. Ltd (“Kuhnil”), one of Korea's leading pharmaceutical companies, pursuant to which Kuhnil purchased 1,500,000 common shares of the Company at a price of $0.80 per share, for total proceeds of $1.2 million.
More
-
January 09, 2006
BioSyntech's BST-CarGel subject of prestigious publication
LAVAL, Québec, Canada — January 9, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX-V: BSY) announced today that BST-CarGel is the subject of a study published in The Journal of Bone and Joint Surgery (JBJS, American Volume). The paper, entitled “Chitosan-Glycerol Phosphate/Blood Implants Improve Hyaline Cartilage Repair in Ovine Microfracture Defects”
More

-
December 29, 2005
BioSyntech grants stock options
LAVAL, Québec, Canada — December 23, 2005 — In accordance with its continuous disclosure obligations, BioSyntech, Inc. (TSX-V: BSY) announces the grant of options to acquire 15,000 common shares of its capital stock at a price of $0.69 per share for a period of five years to each of its four independent directors, namely:
More
-
November 28, 2005
Letter to Shareholders
Dear Shareholder,
In the second quarter, we made considerable progress on our strategic plan for fiscal 2006, both at the corporate and at the scientific level. This success can be summed up in the following four initiatives:
More
-
November 28, 2005
BioSyntech reports its second quarter results
LAVAL, Québec, Canada — November 28, 2005 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) today reported its results for its second quarter ended September 30, 2005
More
-
November 16, 2005
BioSyntech receives approval for Canadian BST-CarGel® pivotal clinical trial
LAVAL, Quebec, Canada — November 16, 2005 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) announced today that it has received approval from Health Canada, Therapeutic Products Directorate, Medical Devices Bureau, to begin its pivotal clinical trial for BST-CarGel®.
More
-
October 18, 2005
BioSyntech signs agreement with one of Korea's leading pharma companies
LAVAL, Quebec, Canada — October 18, 2005 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) today announced the signing of a letter of agreement with Kuhnil Pharma Co. Ltd (“Kuhnil”), one of Korea's leading pharmaceutical companies, pursuant to which Kuhnil will purchase 1,500,000 common shares of the Company at a price of $0.80 per share, for total proceeds of $1.2 million.
More
-
September 22, 2005
BioSyntech updates shareholders at the Annual General Meeting
LAVAL, Quebec, Canada — September 21, 2005 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) was pleased to greet and update its shareholders at the Company’s Annual General Meeting, held in Montreal today.
More
-
September 20, 2005
BioSyntech retains leading investor relations firm
LAVAL, Quebec, Canada — September 20, 2005 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) today announced that it has retained the Equicom Group Inc. (“Equicom”) to provide the Company with strategic investor relations and financial communications services.
More
-
September 06, 2005
BioSyntech announces closing of private placement
LAVAL, Quebec, Canada — (BUSINESS WIRE) — September 6, 2005 — Further to its press release of August 24, 2005, BioSyntech, Inc. (TSX Venture: “BSY”) is pleased to announce the closing of the private placement of 7,500,000 common shares at a price of $0.80 per share by Nicholas Piramal India Limited (“NPIL”).
More
-
August 24, 2005
Nicholas Piramal India Limited and BioSyntech, Inc. Announce signing of formal agreements
LAVAL, Quebec, Canada and Mumbai, India — (BUSINESS WIRE) — August 24, 2005 — Further to its press release of July 7, 2005, BioSyntech, Inc. (TSX Venture: “BSY”) is pleased to announce that the final agreements with respect to the private placement of 7,500,000 common shares of the company at a price of CDN$0.80 per share by Nicholas Piramal India Limited (“NPIL”) have been signed today. Closing will occur as soon as regulatory approvals has been obtained in Canada and India.
More
-
July 07, 2005
BioSyntech, Inc. and Nicholas Piramal India Limited Announce Letter of Intent
BioSyntech, Inc. (TSX VENTURE:BSY) has signed a letter of intent with Nicholas Piramal India Limited ("NPIL"), one of India's leading pharmaceutical companies, pursuant to which NPIL will subscribe to 7,500,000 common shares of the company at a price of C$0.80 per share. NPIL's post-issue shareholding will be approximately 17% of issued shares.
More
-
May 10, 2005
BioSyntech files application for investigational testing authorization (ITA) for Canadian multi-center clinical trial for BST-CarGel®.
BioSyntech, Inc (TSX Venture Exchange "BSY.V") is seeking approval from Health Canada to begin a pivotal clinical trial for its cartilage repair device, BST-CarGel®.
More
-
March 07, 2005
BioSyntech signs agreement with MedQualis as BST-DermOnTM and BST-InPodTM clinical trial CRO, and with the LIO (Imaging and Orthopaedics Research Laboratory) for BST-InPodTM biomechanical outcome assessment
BIOSYNTECH (TSX Venture Exchange 'BSY') is pleased to announce the appointment of MedQualis, a contract research organization (CRO) to support BioSyntech in their upcoming BST-DermOn™ and BST-InPod™ Canadian clinical trials.
More
-
January 24, 2005
BioSyntech enhances management team as product candidates move towards commercialization
BIOSYNTECH (TSX Venture Exchange: BSY) announces the appointment of three new members to its management team as the Company gears up for the commercialization in Canada and Europe of BST-CarGel™ in 2006 and continues development of its other product candidates. Mr. Gilles Chaumillon, PhD, MBA, is appointed Senior Director, Project Management, with overall responsibility for all projects while Ms. Geneviève Hamel becomes Director, Project Management with responsibilities that include a particular focus on BST-CarGel™ . Together, they have the responsibility to bring to term our ...
More

-
December 21, 2004
BioSyntech receives first tranche of $1 million from La Financière du Québec
BIOSYNTECH (TSX Venture Exchange: BSY) announces that La Financière du Québec has paid out the first tranche of $1million of the $2.5-million venture loan that it granted the Company on March 15, 2004. In accordance with the terms of this loan, La Financière du Québec has been granted an option, for a five-year period, to acquire 300,000 shares of the Company at $1.25 per share.
More
-
November 10, 2004
Dr Michael Buschmann to receive the Innovator Prize for 2004 from ADRIQ
BIOSYNTECH (TSX Venture Exchange: BSY) is pleased to announce that Michael D. Buschmann, Professor of Chemical Engineering and Biomedical Engineering at Ecole Polytechnique and Vice-President, Discovery at BioSyntech will receive the Innovator Prize for 2004 from the Association of Industrial Research of Quebec (ADRIQ) at the 14th ADRIQ Gala in Montreal on November 25.
More
-
September 23, 2004
Annual General Meeting of Shareholders: BioSyntech focuses on maximizing potential revenues
At its annual general meeting of shareholders, BioSyntech (TSX Venture Exchange: BSY) explained its strategy for maximizing potential revenues from its lead products, indicated its intention of forming a strategic distribution alliance with a global partner and outlined important achievements for 2004 including the completion of $3.8 million in financing in March 2004.
More
-
September 01, 2004
BioSyntech signs CATO Research as BST-CarGel® clinical trial CRO
BIOSYNTECH (TSX Venture Exchange ‘BSY’) is pleased to announce the signing of a Master Service Agreement with Cato Research Ltd., a contract research organization (CRO) that will support BioSyntech in their upcoming BST-CarGel® clinical trials.
More
-
August 30, 2004
BioSyntech quarterly results and highlights
BIOSYNTECH (TSX Venture Exchange: BSY) released today its first quarter financial results for the period ending June 30, 2004, including recent operating highlights. The documents can be consulted at www.sedar.com or at www.biosyntech.com
More
-
July 12, 2004
Message from Mr. Claude Leduc, CEO of BioSyntech
At a presentation to shareholders and analysts held in Montreal today, Mr Claude Leduc, President and CEO of BioSyntech, Inc, introduced the company's new strategic plan and made the following statements:
More
-
June 23, 2004
BioSyntech, Inc.: Delisting from OTCBB
BioSyntech, Inc (TSX Venture Exchange "BSY.S" - OTCBB:"BSYI") announces that it has terminated the registration of its common shares from the US equity markets effective on June23, 2004.
More

|